"Each client is unique and requires an individual approach. Guided by this philosophy, our specialists develop intelligent and 100% efficient multidisciplinary programs in preclinical drug research and safety evaluation"
QT shift and probabilistic method: powerful approaches for detection of QT prolongation in a most reliable manner. >>>
TDPscreen: in silico modeling for prediction of torsadogenic profiles
>>>
Founded in 1973, CERB has developed to a leading international contract research organization (CRO) in the fields of preclinical pharmacology and toxicology. Taking on the challenges of modern drug development CERB has created its distinctive image of a major service provider to the pharmaceutical industry in the context of innovative biomedical research.
Our toxicology department has also proven to be a valuable partner to other branches, such as chemical and agro-chemical industries, in the field of regulatory safety assessment.
.
For the pharmaceutical industry, CERB takes advantage of its sophisticated synergy between pharmacology and toxicology resources to provide complete pre-phase I packages for a new molecule in an economic and timely manner. Having developed/validated more than 200 models and techniques in pharmacology and toxicology we take on any challenge of specialized approaches fitting the requirements of your compound. A fully equipped chemical analysis unit assures back-up support for drug quantification in chemical or biological matrices as well as biomarker verification.
Our main assets are:
- high quality of scientific and administrative performance
- continuous innovation through targeted scientific input
- a network of independent, internationally renowned experts and cooperations
- the dedication to provide custom-made answers
- reactivity and flexibility
Last publication: "A step towards characterisation of electrophysiological profile of torsadogenic drugs" >>>
SOFAQ (Société française d'Assurance Qualité) December 2011: Automated analysis of audit trail >>>
Eurotox Paris 29 August 2011 "How to proceed? Application to cardiovascular system: Integrating safety pharmacology in the design of regulatory toxicology studies: the pros and cons" >>>
SPS Innsbruck September 2011 "The Importance of Using the Right Technology for the Right Species When Evaluating the Sleep" >>>
Bioluminescence and fluorescence in preclinical safety studies: possible applications - SPS 2011 >>>
Interdisciplinarity and refinement of preclinical oncology models in rodents - Berder 2011 >>>
QT shift and probabilistic methods in guinea pigs - SPS 2011 >>>
Optimized methodology for drug discrimination assessment in the rat - SPS 2011 >>>
Evaluation of 5-fluorouracil effects on tumor growth in a HTC116-luc2 orthotopic colorectal cancer model in mice - Mumbai 2011 >>>